Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Antiviral activity of 3(2H)- and 6-chloro-3(2H)-isoflavenes against highly diverged, neurovirulent vaccine-derived, type2 poliovirus sewage isolates.

Shulman LM, Sofer D, Manor Y, Mendelson E, Balanant J, Salvati AL, Delpeyroux F, Fiore L.

PLoS One. 2011;6(5):e18360. doi: 10.1371/journal.pone.0018360. Epub 2011 May 25.

2.

Antiviral activity of substituted homoisoflavonoids on enteroviruses.

Tait S, Salvati AL, Desideri N, Fiore L.

Antiviral Res. 2006 Dec;72(3):252-5. Epub 2006 Jul 28.

PMID:
16934879
3.

Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus.

Salvati AL, De Dominicis A, Tait S, Canitano A, Lahm A, Fiore L.

Antimicrob Agents Chemother. 2004 Jun;48(6):2233-43.

4.

Gene correction of integrin beta4-dependent pyloric atresia-junctional epidermolysis bullosa keratinocytes establishes a role for beta4 tyrosines 1422 and 1440 in hemidesmosome assembly.

Dellambra E, Prislei S, Salvati AL, Madeddu ML, Golisano O, Siviero E, Bondanza S, Cicuzza S, Orecchia A, Giancotti FG, Zambruno G, De Luca M.

J Biol Chem. 2001 Nov 2;276(44):41336-42. Epub 2001 Aug 24.

5.

Activation of gp130 signaling in vivo by the IL-6 super-agonist K-7/D-6 accelerates repopulation of lymphoid organs after irradiation.

Frasca D, Doria G, Barattini P, Guidi F, Salvati AL, Toniatti C, Ciliberto G.

Eur J Immunol. 1999 Jan;29(1):300-10.

6.

Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.

Toniatti C, Cabibbo A, Sporena E, Salvati AL, Cerretani M, Serafini S, Lahm A, Cortese R, Ciliberto G.

EMBO J. 1996 Jun 3;15(11):2726-37.

7.

Coupling protein design and in vitro selection strategies: improving specificity and affinity of a designed beta-protein IL-6 antagonist.

Martin F, Toniatti C, Salvati AL, Ciliberto G, Cortese R, Sollazzo M.

J Mol Biol. 1996 Jan 12;255(1):86-97.

PMID:
8568877
8.

The molecular design of human IL-6 receptor antagonists.

Lahm A, Savino R, Salvati AL, Cabibbo A, Ciapponi L, Demartis A, Toniatti C, Paonessa G, Altamura S, Ciliberto G.

Ann N Y Acad Sci. 1995 Jul 21;762:136-50; discussion 150-1. No abstract available.

PMID:
7668525
9.

Interleukin-6 (IL-6) antagonism by soluble IL-6 receptor alpha mutated in the predicted gp130-binding interface.

Salvati AL, Lahm A, Paonessa G, Ciliberto G, Toniatti C.

J Biol Chem. 1995 May 19;270(20):12242-9.

10.

Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling.

Paonessa G, Graziani R, De Serio A, Savino R, Ciapponi L, Lahm A, Salvati AL, Toniatti C, Ciliberto G.

EMBO J. 1995 May 1;14(9):1942-51.

11.

The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6.

Martin F, Toniatti C, Salvati AL, Venturini S, Ciliberto G, Cortese R, Sollazzo M.

EMBO J. 1994 Nov 15;13(22):5303-9.

12.

Oncostatin M binds directly to gp130 and behaves as interleukin-6 antagonist on a cell line expressing gp130 but lacking functional oncostatin M receptors.

Sporeno E, Paonessa G, Salvati AL, Graziani R, Delmastro P, Ciliberto G, Toniatti C.

J Biol Chem. 1994 Apr 15;269(15):10991-5.

13.

Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation.

Savino R, Lahm A, Salvati AL, Ciapponi L, Sporeno E, Altamura S, Paonessa G, Toniatti C, Ciliberto G.

EMBO J. 1994 Mar 15;13(6):1357-67.

Supplemental Content

Loading ...
Support Center